Nasal Vaccine Against Pseudomonas aeruginosa in Healthy Volunteers
Author Information
Author(s): Ulrich Baumann, Kerstin Göcke, Britta Gewecke, Joachim Freihorst, Bernd Ulrich von Specht
Primary Institution: Hanover Medical School
Hypothesis
Does a nasal vaccine based on outer membrane proteins induce a lasting antibody response in the lower airways?
Conclusion
The nasal OprF-OprI vaccine induces a lasting antibody response at both systemic and airway mucosal sites.
Supporting Evidence
- The vaccine was well tolerated and elicited a reliable immune response.
- Antibodies were detectable in all vaccinees even 1 year after vaccination.
- The nasal booster group had a better long-term response with bronchial antibodies.
Takeaway
This study tested a nasal vaccine to help protect against lung infections in people with cystic fibrosis, and it showed that the vaccine can help the body make antibodies for a long time.
Methodology
12 healthy volunteers received 2 nasal vaccinations and were assessed for antibody levels in induced sputum and bronchoalveolar lavage.
Limitations
The study's findings may not apply to infants and young children, and the presence of antibodies does not guarantee protection.
Participant Demographics
12 male, healthy subjects with a mean age of 24.3 years.
Statistical Information
P-Value
0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website